Cassava Sciences appoints Rick Barry as CEO; Claude Nicaise becomes Chairman

FILANA THERAPEUTICS, INC.

Richard Barry named CEO effective September 6, 2024; previously Executive Chairman and director since June 2021.
Board separates CEO and Chairman roles; Claude Nicaise, M.D. appointed Chairman.
Dr. Nicaise served as director since Dec 2023; held regulatory roles at Alexion and Bristol-Myers Squibb.
First Phase 3 trial of simufilam (n=804) topline expected by end of 2024; second Phase 3 (n=1,125) by mid-2025.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard (Rick) Barry

Chief Executive Officer

FLNA · FILANA THERAPEUTICS, INC.

Effective: 2024-09-06
Filed: September 9, 2024, 7:59 PM ET

On September 9, 2024, Cassava Sciences, Inc. (“Cassava” or the “Company”) announced that the Company’s Board of Directors has concluded its search for a Chief Executive Officer (“CEO”) and has appointed Richard (Rick) Barry as the Company’s CEO.

Appointed

Claude Nicaise

Chairman

FLNA · FILANA THERAPEUTICS, INC.

Filed: September 9, 2024, 7:59 PM ET

the Board has appointed Claude Nicaise, M.D., as its Chairman.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard (Rick) Barry was appointed as Chief Executive Officer at FILANA THERAPEUTICS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On September 9, 2024, Cassava Sciences, Inc. (“Cassava” or the “Company”) announced that the Company’s Board of Directors has concluded its search for a Chief Executive Officer (“CEO”) and has appointed Richard (Rick) Barry as the Company’s CEO.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Claude Nicaise was appointed as Chairman at FILANA THERAPEUTICS, INC..

Action: appointed
Role: Chairman

Exact text from the filing

the Board has appointed Claude Nicaise, M.D., as its Chairman.

View on SEC.gov

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001171843-24-005116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.